Learn, Analyse & Invest
only with
only with
+91
Download Orca
Supha Pharmachem Ltd.
Supha Pharmachem
₹ 0.00
0.00 (0.00)%
NSE
BSE
Trading
Small-cap - With a market cap of ₹31.75 Cr.
| EX-Date | Purpose |
|---|---|
| 11 05 2021 | Audited Results |
| 20 05 2021 | Preferential Issue of shares & Inter alia, subject to the approval of the shareholders at the ensuing Annual General Meeting of the company. 2.and take on record the resignation of Mr. Siddharth Shah (DIN: 01343122) from the position of the Managing Director of the Company. 3. the raising of funds by issue of shares on a preferential basis or by way of qualified institutions placement up to INR 100 crores. 4.Any other matter with the permission of the chair. |
| 07 07 2021 | Quarterly Results |
| 02 11 2021 | Quarterly Results |
| 12 11 2021 | Quarterly Results (Revised) |
| 09 02 2022 | Quarterly Results |
| 30 05 2022 | Audited Results |
| 12 08 2022 | Quarterly Results |
| 04 11 2022 | Quarterly Results |
| 07 02 2023 | Quarterly Results |
| 30 05 2023 | Audited Results |
| 23 06 2023 | Stock Split & Bonus issue Inter alia, to consider and approve :- 1. issue of Bonus Shares to the existing Equity Shareholders of the Company. 2. Sub-division of Shares/ Stock Split of the Company. 3. Increasing of borrowing limit from INR 50 Crores to INR 1000 Crores by issuance of debt securities ie. Non -Convertible Debentures(NCD), Bank Term Loans etc. 4. Limit for investment by way of acquisition of Asset such as Plant &, Machinery, securities, etc upto INR 1000 Crores. |
| 12 08 2023 | Quarterly Results |
| 05 09 2023 | Inter alia to transact the following business: 1. To appoint Mr. Adarsh Deepak Munjal (DIN: 07304004) as a Whole Time Director of the Company for a period of 3 years w.e.f. 05.09.2023 subject to the approval of the shareholders at the ensuing Extra Ordinary General Meeting of the company. 2. To consider and take on record the resignation of Dr. Vilas Ramkrishna Lokhande (DIN: 01228041) from the position of Whole Time Director of the Company. 3. Any other matter with the permission of the chair. |
| 11 11 2023 | Quarterly Results |
| 08 01 2024 | Stock Split |
| 14 02 2024 | Quarterly Results |
| 07 03 2024 | Inter alia to consider acquisition of manufacturing facility near hyderabad, producing intermediates for the Pharmaceutical Industry. |
| 14 11 2024 | Quarterly Results |
| 22 01 2025 | Inter alia, to consider and approve:- (1) Raising funds by way of issue of fresh equity shares through Right Issue basis along-with other matter, if any, as may be permitted under applicable laws, subject to such regulatory/statutory approvals as may be required. 2) Any other business with the permission of the Chair. |
| 14 02 2025 | Quarterly Results |
| 07 04 2025 | Rights Issue |
| 24 04 2025 | Inter alia, to consider and approve:- 1. To Approve the Letter of Offer (LOF) for the proposed Rights Issue of 49,19,04,000 Equity Shares of Re. 1/- each, aggregating to 4919.04 lakhs for shareholders of the Company. 2. Any other item with the permission of the Chair and Majority of Directors. |
| 30 05 2025 | Audited Results |
| 04 08 2025 | Quarterly Results |
| 22 09 2025 | Rights Issue & Increase in Authorised Capital |
| 14 11 2025 | Quarterly Results |
| 14 02 2026 | Quarterly Results |
| 25 02 2026 | Quarterly Results(Cancelled) (Cancelled) |
| 09 03 2026 | Quarterly Results |
| 30 03 2026 | Quarterly Results |
News
